Schultz, K. R. and Miklos, D. B. and Fowler, D. and Cooke, K. and Shizuru, J. and Zorn, E. and Holler, E. and Ferrara, Y. and Shulman, H. and Lee, S. Y. and Martin, P. and Filipovich, A. H. and Flowers, Mary E.D. and Weisdorf, D. and Couriel, D. and Lachenbruch, P. A and Mittleman, B. and Vogelsang, G. B. and Pavletic, S. Z. (2006) Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12 (2). pp. 126-137. ISSN 1083-8791, 1523-6536
Full text not available from this repository. (Request a copy)Abstract
Biology-based markers that can be used to confirm the diagnosis of chronic graft-versus-host disease (GVHD) or monitor progression of the disease could help in the evaluation of new therapies. Biomarkers have been defined as any characteristic that is objectively measured and evaluated as an indicator of a normal biologic or pathogenic process, a pharmacologic response to a therapeutic intervention, or a surrogate end point intended to substitute for a clinical end point. The following applications of biomarkers could be useful in chronic GVHD clinical trials or management: (1) predicting response to therapy; (2) measuring disease activity and distinguishing irreversible damage from continued disease activity; (3) predicting the risk of developing chronic GVHD; (4) diagnosing chronic GVHD: (5) predicting the prognosis of chronic GVHD; (6) evaluating the balance between GVHD and graft-versus-leukemia effects (graft-versus-leukemia or GVT); and (7) serving as a surrogate end point for therapeutic response. Such biomarkers can be identified by either hypothesis-driven testing or by high-throughput discovery-based methods. To date, no validated biomarkers have been established for chronic GVHD, although several candidate biomarkers have been identified from limited hypothesis-driven studies. Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials. (C) 2006 American Society for Blood and Marrow Transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGEN; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; MONOCLONAL-ANTIBODY; GENE POLYMORPHISMS; FEMALE DONORS; LABIAL SALIVA; BLOOD; graft-versus-host disease; biomarkers |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 11 Feb 2021 13:19 |
| Last Modified: | 11 Feb 2021 13:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/34965 |
Actions (login required)
 |
View Item |
